The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions

Cancer Immunology, Immunotherapy

Volumn 67, Issue 7, 2018, Pages 1079-1090

  Zhang, Tong ^a   Song, Xiaomin ^a   Xu, Lanlan ^a   Ma, Jie ^a   Zhang, Yanjuan ^a   Gong, Wenfeng ^a   Zhang, Yilu ^a   Zhou, Xiaosui ^a   Wang, Zuobai ^a   Wang, Yali ^a   Shi, Yingdi ^a   Bai, Huichen ^a   Liu, Ning ^a   Yang, Xiaolong ^a   Cui, Xinxin ^a   Cao, Yanping ^a   Liu, Qi ^a   Song, Jing ^a   Li, Yucheng ^a   Tang, Zhiyu ^a   Guo, Mingming ^a   Wang, Lai ^a   Li, Kang ^a   more..

^a Zhong Guan Cun Life Science Park   (China)

Author keywords

Antibody; Cancer therapy; Fc RI; Macrophages; PD 1

Indexed keywords

ANTINEOPLASTIC MONOCLONAL ANTIBODY; BGB A317 ANTIBODY; BGB A317 IMMUNOGLOBULIN G4 S228P ANTIBODY; FC RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL FUNCTIONS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ISOLATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED NOD; MICE, SCID; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IGG; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85045842204     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-018-2160-x     Document Type: Article

References (45)

1. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. 10.1126/science.1203486
2. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Investig 117:1137–1146. 10.1172/JCI31405
3. Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125:3384–3391. 10.1172/JCI80011
4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol 26:677–704. 10.1146/annurev.immunol.26.021607.090331
5. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. 10.1056/NEJMoa1200690
6. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028. 10.1056/NEJMoa1501824
7. McDermott DF, Drake CG, Sznol M et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33:2013–2020. 10.1200/JCO.2014.58.1041
8. Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. 10.1056/NEJMoa1602252
9. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026. 10.1056/NEJMoa1613683
10. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725. 10.1182/blood-2008-09-179754
11. Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–5649. 10.1182/blood-2012-01-380121
12. Labrijn AF, Buijsse AO, van den Bremer ET et al (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27:767–771. 10.1038/nbt.1553
13. Silva JP, Vetterlein O, Jose J, Peters S, Kirby H (2015) The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation. J Biol Chem 290:5462–5469. 10.1074/jbc.M114.600973
14. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28:285–295. 10.1016/j.ccell.2015.08.004
15. Leidi M, Gotti E, Bologna L et al (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182:4415–4422. 10.4049/jimmunol.0713732
16. Dai X, Jayapal M, Tay HK et al. (2009) Differential signal transduction, membrane trafficking, and immune effector functions mediated by FcgammaRI versus FcgammaRIIa. Blood 114:318–327. 10.1182/blood-2008-10-184457
17. van der Poel CE, Spaapen RM, van de Winkel JG, Leusen JH (2011) Functional characteristics of the high affinity IgG receptor, FcgammaRI. J Immunol 186:2699–2704. 10.4049/jimmunol.1003526
18. Grell M, Scheurich P, Meager A, Pfizenmaier K (1993) TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis. Lymphokine Cytokine Res 12:143–148
19. Boekhoudt GH, Frazier-Jessen MR, Feldman GM (2007) Immune complexes suppress IFN-gamma signaling by activation of the FcgammaRI pathway. J Leukoc Biol 81:1086–1092. 10.1189/jlb.0906543
20. Swisher JF, Haddad DA, McGrath AG, Boekhoudt GH, Feldman GM (2014) IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcgammaRI. mAbs 6:1377–1384. 10.4161/19420862.2014.975657
21. Arango Duque G, Descoteaux A (2014) Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 5:491. 10.3389/fimmu.2014.00491
22. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW (2012) Crosstalk between human IgG isotypes and murine effector cells. J Immunol 189:3430–3438. 10.4049/jimmunol.1200356
23. McKnight AJ, Macfarlane AJ, Dri P, Turley L, Willis AC, Gordon S (1996) Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. J Biol Chem 271:486–489
24. Murray PJ, Allen JE, Biswas SK et al (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41:14–20. 10.1016/j.immuni.2014.06.008
25. Lopez AF, Strath M, Sanderson CJ (1984) Differentiation antigens on mouse eosinophils and neutrophils identified by monoclonal antibodies. Br J Haematol 57:489–494
26. Zhang QW, Liu L, Gong CY, Shi HS, Zeng YH, Wang XZ, Zhao YW, Wei YQ (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PloS One 7:e50946. 10.1371/journal.pone.0050946
27. Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6:1670–1690. 10.3390/cancers6031670
28. Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41:49–61. 10.1016/j.immuni.2014.06.010
29. Ruffell B, Coussens LM (2015) Macrophages and therapeutic resistance in cancer. Cancer Cell 27:462–472. 10.1016/j.ccell.2015.02.015
30. Bostrom MM, Irjala H, Mirtti T, Taimen P, Kauko T, Algars A, Jalkanen S, Bostrom PJ (2015) Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer. PloS One 10:e0133552. 10.1371/journal.pone.0133552
31. Zhao Q, Kuang DM, Wu Y, Xiao X, Li XF, Li TJ, Zheng L (2012) Activated CD69+ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol 188:1117–1124. 10.4049/jimmunol.1100164
32. Tsujikawa T, Kumar S, Borkar RN et al. (2017) Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis. Cell Rep 19:203–217. 10.1016/j.celrep.2017.03.037
33. Nishimura H, Honjo T (2001) PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22:265–268
34. Davies AM, Sutton BJ (2015) Human IgG4: a structural perspective. Immunol Rev 268:139–159. 10.1111/imr.12349
35. Wang C, Thudium KB, Han M et al. (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2:846–856. 10.1158/2326-6066.CIR-14-0040
36. Lux A, Seeling M, Baerenwaldt A et al. (2014) A humanized mouse identifies the bone marrow as a niche with low therapeutic IgG activity. Cell Rep 7:236–248. 10.1016/j.celrep.2014.02.041
37. Isaacs JD, Wing MG, Greenwood JD, Hazleman BL, Hale G, Waldmann H (1996) A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans. Clin Exp Immunol 106:427–433
38. Sutterwala FS, Noel GJ, Salgame P, Mosser DM (1998) Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. J Exp Med 188:217–222
39. Gu Z, Chhabra AY, Alard P, Warner DR, Kosiewicz MM (2013) FcgammaRI is required for TGFbeta2-treated macrophage-induced tolerance. Immunobiology 218:1200–1206. 10.1016/j.imbio.2013.04.003
40. Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ (2015) An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. mAbs 7:494–504. 10.1080/19420862.2015.1022692
41. Shultz LD, Schweitzer PA, Christianson SW et al. (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191
42. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P (2014) Contribution of human FcgammaRs to disease with evidence from human polymorphisms and transgenic animal studies. Front Immunol 5:254. 10.3389/fimmu.2014.00254
43. Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8:328rv4. 10.1126/scitranslmed.aad7118
44. Luo L, Wu X, Zhang T et al (2017) Abstract 5626: Investigation of T cell activation by anti-human PD-1 antibodies nivolumab, pembrolizumab and BGB-A317 using tumor-infiltrating lymphocytes (TILs) from colorectal cancer and colorectal liver metastasis patients. Cancer Res 77:5626. 10.1158/1538-7445.am2017-5626
45. Arlauckas SP, Garris CS, Kohler RH et al (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med. 10.1126/scitranslmed.aal3604